ABSENCE OF SEVERE HEMATOLOGICAL TOXICITY DURING FIRST LINE TREATMENT PREDICTS LOW CHANCE ON SEVERE TOXICITY DURING SECOND LINE ALKYLATING CHEMOTHERAPY IN GLIOBLASTOMA

F. E. L. van den Elzen, N. Grun, J. Osinga, A. N. van der Vegt, L. de Glopper, M. Sintemaartensdijk, M. E. van Linde, T. J. Postma, M. Schuur, M. C. M. Kouwenhoven

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)8-8
JournalNeuro-oncology
Volume23
Publication statusPublished - Sept 2021

Cite this